SIKTA CHATTOPADHYAYA

Dr. SIKTA CHATTOPADHYAYA

University of Manitoba, Winnipeg, Manitoba, Canada
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
SIKTA CHATTOPADHYAYASIKTA CHATTOPADHYAYA
SIKTA CHATTOPADHYAYA
RNRaghu Sundaresan Nagalingam
Raghu Sundaresan Nagalingam
DLD. Allison Ledingham
D. Allison Ledingham
TMTeri L. Moffatt
Teri L. Moffatt
DADanah Sufian Al-Hattab
Danah Sufian Al-Hattab
MCMichael Paul Czubryt
Michael Paul Czubryt
Fibrosis is an energy-intensive process requiring the activation of fibroblasts to myofibroblasts, resulting in the increased synthesis of extracellular matrix proteins. Little is known about the transcriptional control of energy metabolism in cardiac fibroblast activation, but glutaminolysis has been implicated in liver and lung fibrosis. Here we explored how pro-fibrotic TGFβ and its effector scleraxis, which drive cardiac fibroblast activation, regulate genes involved in glutaminolysis, particularly the rate-limiting enzyme glutaminase (GLS1). The GLS1 inhibitor CB-839 attenuated TGFβ-induced fibroblast activation. Cardiac fibroblast activation to myofibroblasts by scleraxis overexpression increased glutaminolysis gene expression, including GLS1, while cardiac fibroblasts from scleraxis-null mice showed reduced expression. TGFβ induced GLS1 expression and increased intracellular glutamine and glutamate levels, indicative of increased glutaminolysis, but in scleraxis knockout cells, these measures were attenuated, and the response to TGFβ was lost. The knockdown of scleraxis in activated cardiac fibroblasts reduced GLS1 expression by 75%. Scleraxis transactivated the human GLS1 promoter in luciferase reporter assays, and this effect was dependent on a key scleraxis-binding E-box motif. These results implicate scleraxis-mediated GLS1 expression as a key regulator of glutaminolysis in cardiac fibroblast activation, and blocking scleraxis in this process may provide a means of starving fibroblasts of the energy required for fibrosis.

23 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
DADanah Sufian Al-Hattab
Danah Sufian Al-Hattab
SIKTA CHATTOPADHYAYASIKTA CHATTOPADHYAYA
SIKTA CHATTOPADHYAYA
MCMichael Paul Czubryt
Michael Paul Czubryt
Fibroblasts are stromal cells found in virtually every tissue and organ of the body. For many years, these cells were often considered to be secondary in functional importance to parenchymal cells. Over the past 2 decades, focused research into the roles of fibroblasts has revealed important roles for these cells in the homeostasis of healthy tissue, and has demonstrated that activation of fibroblasts to myofibroblasts is a key step in disease initiation and progression in many tissues, with fibrosis now recognized as not only an outcome of disease, but also a central contributor to tissue dysfunction, particularly in the heart and lungs. With a growing understanding of both fibroblast and myofibroblast heterogeneity, and the deciphering of the humoral and mechanical cues that impact the phenotype of these cells, fibroblast biology is rapidly becoming a major focus in biomedical research. In this review, we provide an overview of fibroblast and myofibroblast biology, particularly in the heart, and including a discussion of pathophysiological processes such as fibrosis and scarring. We then discuss the central role of Canadian researchers in moving this field forwards, particularly in cardiac fibrosis, and highlight some of the major contributions of these individuals to our understanding of fibroblast and myofibroblast biology in health and disease.

1 November 2026 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
DADanah Sufian Al-Hattab
Danah Sufian Al-Hattab
TMTeri L. Moffatt
Teri L. Moffatt
DMD. Allison Milosevic
D. Allison Milosevic
SIKTA CHATTOPADHYAYASIKTA CHATTOPADHYAYA
SIKTA CHATTOPADHYAYA
KOKimberley A. O’HAra
Kimberley A. O’HAra
MCMichael Paul Czubryt
Michael Paul Czubryt
Scleraxis potently drives cardiac fibrosis, yet lacks any known function in the vasculature despite being highly upregulated in pathologies marked by increased vessel stiffness. Scleraxis overexpression in vascular smooth muscle cells in vivo increased their proliferation while also increasing measures of vascular stiffness. Scleraxis and angiotensin II together also increased stiffness, but this effect was related to increased contractile gene expression. This work provides the first description of scleraxis’ role in the vasculature.